Company / Interest Expense
ALNYLAM PHARMACEUTICALS, INC. Interest Expense History
FY2020-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$121.2M
FY2023
5-year range
$0 / $121.2M
FY2020-FY2023
Trend
+43.5%
vs FY2022
Sector context
#10 of 44
Health Care
What the data says
ALNYLAM PHARMACEUTICALS, INC.'s interest expense of $121M is higher than 77% of companies in the Health Care sector (FY2023). Increased from $0 to $121M over the past 2 years.
Based on SEC 10-K filings.
$121M in FY2023. Top quartile in the Health Care sector.
Increased from $0 to $121M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 44This company $121.2M Sector average $291.0M
▼
-58.3% below sector average
Key checks
Key Insights
- In FY2023, interest expense increased 43.5% year-over-year.
- Ranks #10 out of 44 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $121.2M | +43.5% |
| FY2022 | $84.5M | - |
| FY2021 | $0 | - |
| FY2020 | $0 | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026